This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): quinupristin and dalfopristin
Description: Synercid, the first streptogramin—the first new antibiotic class available to the United States medical community in over a decade. Synercid exhibits good activity against methicillin-sensitive and -resistant Staphylococcus aureus, streptococci, and Enterococcus faecium (including vanocomycin-resistant strains); and poor activity against Enterococcus faecalis and Gram-(-) bacteria.
Synercid is an injectable formulation of 2 streptogramin (Quinupristin and Dalfopristin) antibiotics. These 2 components act synergistically to kill bacteria by inhibiting bacterial ribosomes involved in protein synthesis. Dalfopristin has been shown to inhibit the early phase of protein synthesis while Quinupristin inhibits the late phase of protein synthesis.
Deal Structure: In October 2010, Pfizer and King Pharmaceuticals announced that they have entered into a definitive merger agreement. In February 2011, Pfizer completed its acquisition of King.
Pink Sheet In Brief: Rhone-Poulenc Rorer Synercid
Additional information available to subscribers only: